O
OrbiMed is a global investment firm exclusively focused on the healthcare sector, investing in companies across biopharmaceuticals, medical technologies, medical devices, diagnostics, and healthcare IT and services. Their strategy involves investing across the entire industry lifecycle, from seed-stage ventures to large public companies, utilizing public equity, private equity, and private credit/royalty strategies.
Portfolio
6
Fund Size
$20B
Top Stage
Series C
Last 12 Mo
1
Stage Distribution
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Aspen Neuroscience | Series C | $115M | Nov 2025 |
| Ottimo Pharma | Series A | $140M | Dec 2024 |
| Angitia Biopharmaceuticals | Series C | $120M | Dec 2024 |
| Caris Life Sciences | Growth | $400M | Jan 2023 |
| Aspen Neuroscience | Series B | $147.5M | May 2022 |
| Aspen Neuroscience | Series A | $70M | Apr 2020 |
Top Co-Investors
ARCH Venture Partners3 shared
Frazier Life Sciences2 shared
Lifeforce Capital2 shared
Legend Capital1 shared
S321 shared
Balyasny Asset Management1 shared
Cormorant Asset Management1 shared
GV (Google Ventures)1 shared
LYFE Capital1 shared
Revelation Partners1 shared
EDBI1 shared
Mirae Asset1 shared
Alexandria Venture Investments1 shared
RTW Investments1 shared
Invus1 shared
Section 321 shared
Braidwell LP1 shared
Last updated: 26 February 2026